SG11201502930XA - Stable pharmaceutical composition of peginterferon alpha-2b - Google Patents

Stable pharmaceutical composition of peginterferon alpha-2b

Info

Publication number
SG11201502930XA
SG11201502930XA SG11201502930XA SG11201502930XA SG11201502930XA SG 11201502930X A SG11201502930X A SG 11201502930XA SG 11201502930X A SG11201502930X A SG 11201502930XA SG 11201502930X A SG11201502930X A SG 11201502930XA SG 11201502930X A SG11201502930X A SG 11201502930XA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
stable pharmaceutical
peginterferon alpha
peginterferon
alpha
Prior art date
Application number
SG11201502930XA
Inventor
Paresh Natwarlal Vadgama
Anjali Deepak Apte-Deshpande
Rustom Sorab Mody
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of SG11201502930XA publication Critical patent/SG11201502930XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201502930XA 2012-10-26 2013-10-25 Stable pharmaceutical composition of peginterferon alpha-2b SG11201502930XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1234KO2012 2012-10-26
PCT/IB2013/059657 WO2014064652A2 (en) 2012-10-26 2013-10-25 Stable pharmaceutical composition of peginterferon alpha-2b

Publications (1)

Publication Number Publication Date
SG11201502930XA true SG11201502930XA (en) 2015-05-28

Family

ID=54208813

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502930XA SG11201502930XA (en) 2012-10-26 2013-10-25 Stable pharmaceutical composition of peginterferon alpha-2b

Country Status (13)

Country Link
US (1) US20150283252A1 (en)
EP (1) EP2911685A2 (en)
JP (1) JP2015535238A (en)
KR (1) KR20150074167A (en)
CN (1) CN104768569A (en)
AU (1) AU2013336206A1 (en)
BR (1) BR112015009453A2 (en)
CA (1) CA2888442A1 (en)
EA (1) EA201590790A1 (en)
MX (1) MX2015005230A (en)
SG (1) SG11201502930XA (en)
WO (1) WO2014064652A2 (en)
ZA (1) ZA201502695B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
RU2017105844A (en) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Stable and soluble compositions of receptor tyrosine kinase inhibitors and methods for their preparation
EP3453390B1 (en) 2016-05-06 2024-02-14 Biodynamic Research Foundation Polymerized drug-containing pharmaceutical composition
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
US11690799B2 (en) 2018-04-19 2023-07-04 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US700314A (en) 1902-01-31 1902-05-20 John H Fedeler Steam-turbine.
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
CZ302005B6 (en) * 1998-03-26 2010-09-01 Schering Corporation Aqueous agent of PEG-interferon alpha conjugate, lyophilizate thereof and product containing it
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
KR100399156B1 (en) 1999-11-19 2003-09-26 주식회사 엘지생명과학 Liquid Formulation of α-Interferon
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1691825B1 (en) 2003-12-11 2011-09-28 Ares Trading S.A. Stabilized interferon liquid formulations
AU2005272862B2 (en) * 2004-08-12 2011-03-10 Merck Sharp & Dohme Corp. Stable pegylated interferon formulation
EP2422770A1 (en) 2006-11-24 2012-02-29 Cadila Healthcare Limited Formulations of peg-interferon alpha conjugates
ATE512660T1 (en) * 2007-03-05 2011-07-15 Cadila Healthcare Ltd COMPOSITIONS WITH PEG-INTERFERON-ALPHA CONJUGATES AND RAFFINOSE AS CRYOPROTECTIVE AGENTS
WO2010064258A2 (en) 2008-12-01 2010-06-10 Intas Biopharmaceuticals Limited Pharmaceutical formulations of interferon conjugates

Also Published As

Publication number Publication date
EA201590790A1 (en) 2015-08-31
BR112015009453A2 (en) 2017-07-04
EP2911685A2 (en) 2015-09-02
CN104768569A (en) 2015-07-08
US20150283252A1 (en) 2015-10-08
WO2014064652A3 (en) 2014-06-12
JP2015535238A (en) 2015-12-10
MX2015005230A (en) 2015-08-14
KR20150074167A (en) 2015-07-01
ZA201502695B (en) 2016-06-29
CA2888442A1 (en) 2014-05-01
AU2013336206A1 (en) 2015-05-07
WO2014064652A2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
ZA201703992B (en) Inhalable pharmaceutical compositions
HK1205690A1 (en) Pharmaceutical composition and administration thereof
IL236024A (en) Benzimidazole-proline derivatives and pharmaceutical compositions comprising them
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
IL236221A (en) Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases
EP2629786A4 (en) Compositions for drug administration
HK1206623A1 (en) Pharmaceutical compositions and treatment of mastitis
EP2832730A4 (en) Mirabegron-containing pharmaceutical composition
HRP20190050T1 (en) Pharmaceutical compositions for combination therapy
ZA201502695B (en) Stable pharmaceutical composition of peginterferon alpha-2b
HRP20180567T1 (en) Pharmaceutical composition of omeprazole
HK1210710A1 (en) Pharmaceutical composition comprising rebamipide
PT3524260T (en) Pharmaceutical compositions for treatment of inappetance
HK1188791A1 (en) Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these
EP2897590A4 (en) Pharmaceutical composition
EP2884963A4 (en) Stable pharmaceutical formulation of cabazitaxel
EP2851078A4 (en) Pharmaceutical composition
GB201407689D0 (en) Pharmaceutical compositions of antihypertensives
ZA201400751B (en) Pharmaceutical composition
HUE043019T2 (en) Pharmaceutical compositions for combination therapy